Oxford University Hospitals is now a highly specialised NHS centre offering CAR-T therapies to people with cancer, after NHS England expanded access to the potentially life-saving treatment. The cutting-edge therapy, which use a patient’s own...
“Le comité de pharmacovigilance (PRAC) de l’Agence européenne des médicaments (EMA) recommande la mise en place de mesures de réduction du risque pour les patients de sexe masculin traités par valproate ou ses dérivés en...
A group of leading institutions will identify and analyse CAR-T patient referral pathways in the UK to recommend future best practice. As the spread and scale of CAR-T therapy widens, there is a need for...
Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products End Date: 14 Jul 2022 Draft Guidance See all of Catapult’s Regulatory Round-up for June 2022 here. Published on the 1st of July...
Reflecting on NHS experience to date with CAR T – Thinkpiece 2.0 The report explores the perspectives of the NHS and industry partners on the adoption of CAR-T in the UK and is based on...
The US Food and Drug Administration (FDA) has issued draft guidance on the development of gene therapy products that incorporate genome editing of somatic cells and chimeric antigen receptor (CAR) T-cell products. The two draft...
More info on RegMedNet.
